Pharmaceutical

AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients

This trial investigated the potential of Nanoscope Therapeutics' MCO-010 to restore vision in patients with retinitis pigmentosa (RP).

Oct 22, 2024 - 04:00
AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients
This trial investigated the potential of Nanoscope Therapeutics' MCO-010 to restore vision in patients with retinitis pigmentosa (RP).
Read the original article

Tags:

Previous Article

Thermo Fisher’s Oncomine gains FDA approval as brain tumor diagnostic

Next Article

Sanofi’s $17bn sale of Opella to US investors advances following government deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Targeted drug greatly slows progression of a brain cancer

STAT+: Targeted drug greatly slows progression of a bra...

Jun 4, 2023

SY-001 by CellOrigin Technology (Hangzhou) for Solid Tu...

Feb 20, 2024

Market cap upturn for top 20 biopharma companies with obesity drug successes in 2023

Market cap upturn for top 20 biopharma companies with o...

Mar 1, 2024